Planas J - Search Results

1

Relationship between Proclarix and the Aggressiveness of Prostate Cancer.

Campistol M, Triquell M, Regis L, Celma A, de Torres I, Semidey ME, Mast R, Mendez O, Planas J, Trilla E, Morote J. Campistol M, et al. Among authors: planas j. Mol Diagn Ther. 2023 Jul;27(4):487-498. doi: 10.1007/s40291-023-00649-y. Epub 2023 Apr 20. Mol Diagn Ther. 2023. PMID: 37081322

2

Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.

Morote J, Esquena S, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX, Planas J, Catalán R, Reventós J. Morote J, et al. Among authors: planas j. Anticancer Drugs. 2005 Sep;16(8):863-6. doi: 10.1097/01.cad.0000173474.82486.74. Anticancer Drugs. 2005. PMID: 16096434

3

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Morote J, et al. Among authors: planas j. J Urol. 2006 May;175(5):1679-83; discussion 1683. doi: 10.1016/S0022-5347(05)00999-7. J Urol. 2006. PMID: 16600728

4

The relationship between daily calcium intake and bone mineral density in men with prostate cancer.

Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX. Planas J, et al. BJU Int. 2007 Apr;99(4):812-5; discussion 815-6. doi: 10.1111/j.1464-410X.2006.06695.x. BJU Int. 2007. PMID: 17378843

5

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R. Morote J, et al. Among authors: planas j. J Urol. 2007 Oct;178(4 Pt 1):1290-5. doi: 10.1016/j.juro.2007.05.129. Epub 2007 Aug 14. J Urol. 2007. PMID: 17698136

6

PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy.

Morote J, Fernández S, Alaña L, Iglesias C, Planas J, Reventós J, Ramón Y Cajal S, Paciucci R, de Torres IM. Morote J, et al. Among authors: planas j. Clin Cancer Res. 2008 May 1;14(9):2617-22. doi: 10.1158/1078-0432.CCR-07-4987. Clin Cancer Res. 2008. PMID: 18451224

7

Is there a relationship between prostate volume and Gleason score?

Mir MC, Planas J, Raventos CX, de Torres IM, Trilla E, Cecchini L, Orsola A, Morote J. Mir MC, et al. Among authors: planas j. BJU Int. 2008 Aug 5;102(5):563-5. doi: 10.1111/j.1464-410X.2008.07696.x. Epub 2008 May 12. BJU Int. 2008. PMID: 18476971

8

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.

Morote J, Planas J, Salvador C, Raventós CX, Catalán R, Reventós J. Morote J, et al. Among authors: planas j. BJU Int. 2009 Feb;103(3):332-5; discussion 335. doi: 10.1111/j.1464-410X.2008.08062.x. Epub 2008 Oct 31. BJU Int. 2009. PMID: 19007366

9

The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.

Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM, Catalán R. Morote J, et al. Among authors: planas j. BJU Int. 2009 Aug;104(4):486-9. doi: 10.1111/j.1464-410X.2009.08378.x. Epub 2009 Feb 10. BJU Int. 2009. PMID: 19220251

10

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J. Planas J, et al. BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22. BJU Int. 2009. PMID: 19549260

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

498 results

Search Page